Claris confirms break-up with Pfizer
This article was originally published in Scrip
Claris Lifesciences has confirmed that its supply agreement with Pfizer has been terminated and it will pursue selling products on its own in the US. Scrip had on 22 August reported that the alliance had been called off and that Pfizer had 'no current plans' to source 'any products' from Claris (scripintelligence.com 22 August 2012).
You may also be interested in...
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.
Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.